Holen Sie sich die Stockscreener-App
0.2809
3.20%
-0.0093
Handel nachbörslich:
.29
0.0091
+3.24%
Scisparc Ltd Aktie (SPRC) Neueste Nachrichten
SciSparc Extends Deadline for Miza III Ventures Deal - TipRanks
SciSparc Ltd. Extends Merger Agreement with AutoMax Motors - TipRanks
SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 1,435.0% in March - Defense World
SciSparc announces resale of 61.21M shares by selling shareholders; shares down - MSN
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - Louisiana First News
SciSparc and Clearmind Advance Cocaine Addiction Treatment with South Korean Patent Application - TipRanks
Is the SciSparc Ltd (NASDAQ:SPRC) stock an investment opportunity? - US Post News
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc Shares Are Soaring Monday: What's Going On? - Benzinga
Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction - Marketscreener.com
SciSparc announces publication of patent via Clearmind collaboration - TipRanks
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine Addiction - Nasdaq
SciSparc Advances Cocaine Treatment Patent Following Successful Preclinical Data - StockTitan
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Extends $2 Million Loan to Support Automax?s Growth Following Automax?s Entry into Direct Import of JAC Electric Vehicles - Marketscreener.com
SciSparc Ltd. Agrees to Sell MitoCareX to N2OFF - TipRanks
SciSparc signs definitive agreement to sell MitoCareX to N2OFF - TipRanks
SciSparc to sell MitoCareX to N2Off for $700,000 - MSN
SciSparc divests MitoCareX stake for $700,000 and stock swa By Investing.com - Investing.com South Africa
SciSparc divests MitoCareX stake for $700,000 and stock swa - Investing.com
SciSparc Ltd. Announces Sale of MitoCareX Shares to N2Off for $700,000 and Stock Exchange Agreement - Nasdaq
SciSparc Signs Definitive Agreement to Sell MitoCareX, - GlobeNewswire
SciSparc's Strategic Exit: How Its MitoCareX Sale Could Deliver $2.3M+ in Value - StockTitan
SciSparc Ltd. announced that it expects to receive $2 million in funding from Yorkville Advisors Global LP - Marketscreener.com
SciSparc Extends $2 Million Loan to Support AutoMax's - GlobeNewswire
SciSparc provides $2 million loan to AutoMax for expansion - Investing.com Australia
SciSparc Enters $4.2M Securities Agreement and Supports AutoMax Expansion with $2M Loan - TipRanks
SciSparc provides $2 million loan to AutoMax for expansion By Investing.com - Investing.com South Africa
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles - The Manila Times
SciSparc extends $2M loan to support AutoMax growth - TipRanks
SciSparc Ltd. Enters $2 Million Loan Agreement with AutoMax Motors to Support Business Expansion - Nasdaq
SciSparc Bets $2M on Electric Vehicle Future with Latest AutoMax Financing - StockTitan
N2OFF to acquire biotech firm MitoCareX in strategic move - Investing.com
SciSparc Ltd. Reaches Favorable Lawsuit Settlement, Secures Cash Compensation and IP Rights - TipRanks
How Are Things Looking For SciSparc Ltd (NASDAQ: SPRC) For The Short Term? - Stocks Register
SciSparc Reveals Favorable Cash Settlement In Lawsuit, Shares Up - Nasdaq
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology - The Manila Times
SciSparc Ltd. Secures Settlement Agreement in Lawsuit Against Former Directors, Retaining Key Intellectual Property Rights - Nasdaq
SciSparc Secures Favorable Settlement in Lawsuit It Filed, - GlobeNewswire
Legal Victory: SciSparc Claims $411K Settlement and Complete IP Control in Strategic Court Win - StockTitan
Investor Ideas New Stocks to Watch in Life Sciences and AI - Investorideas.com newswire
SPRC’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
SciSparc Ltd (SPRC) Shares Soar Above 1-Year High - The News Heater
Views of Wall Street’s Leading Experts on SciSparc Ltd - SETE News
Behind SciSparc Ltd’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - GlobeNewswire
SciSparc and Clearmind’s Patent Publication Marks Progress in Binge Behavior Treatment - TipRanks
SciSparc Ltd.-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - Marketscreener.com
SciSparc Ltd. and Clearmind Medicine Inc. Collaborate on Patent Application for Innovative Combination Therapy to Address Binge Behaviors - Nasdaq
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico - The Manila Times
SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN
Jeffs' Brands Negotiates $11.8M Sale of Smart Repair Pro to Canadian Company in Major Restructuring - StockTitan
Minerva Neurosciences (NASDAQ:NERV) vs. SciSparc (NASDAQ:SPRC) Financial Contrast - Defense World
SciSparc gets Nasdaq extension to regain compliance - MSN
3.89%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):